Compare BYAH & SHPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BYAH | SHPH |
|---|---|---|
| Founded | 2016 | 2012 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9M | 2.1M |
| IPO Year | 2023 | 2022 |
| Metric | BYAH | SHPH |
|---|---|---|
| Price | $2.17 | $5.07 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 11.8K | ★ 40.8K |
| Earning Date | 07-24-2026 | 11-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.05 | $0.38 |
| 52 Week High | $6.64 | $8.88 |
| Indicator | BYAH | SHPH |
|---|---|---|
| Relative Strength Index (RSI) | 46.35 | 58.29 |
| Support Level | $1.97 | $2.83 |
| Resistance Level | $3.26 | $5.67 |
| Average True Range (ATR) | 0.16 | 0.46 |
| MACD | -0.01 | -0.04 |
| Stochastic Oscillator | 43.97 | 84.35 |
Park Ha Biological Technology Co Ltd is engaged in developing its private skincare label, direct skincare products sales, and franchise alliances promotions. Its Park Ha brand focuses on providing solutions for problematic skin. The company's Operating Subsidiaries provide skincare and cosmetic products under its brand, Park Ha, in China. Its Operating Subsidiaries develop its proprietary beauty products and offer complementary after-sales beauty services in its physical stores.
Shuttle Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company leveraging its proprietary technology to develop novel therapies designed to cure cancers. The company has one operating segment with a focus on the development of novel drug therapies, including cancer therapies, extending new applications of radiation therapy, and other drug development, including through the use of the Molecule.ai platform by the company as well as licensing the right to use Molecuile.ai to others. The company's goal is to extend the benefits of cancer treatments with surgery, radiation therapy, chemotherapy and immunotherapy. Radiation therapy (RT) is one of the effective modalities for treating cancers. Its pipeline includes: Ropidoxuridine, HDAC Inhibitors, PSMA-B, and PC-Rad Test.